The Three P’s: Parotid, PD-L1, and Pembrolizumab
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
| Published in: | Case Reports in Oncological Medicine |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Online Access: | http://dx.doi.org/10.1155/2019/2305315 |